Crohn’s disease investigational drug shows promise, phase II trial shows Mongersen, an investigational agent being developed by Celgene, has been tested in Crohn’s disease and researchers have seen clinical remission in some patients.…
Optimising therapy for inflammatory bowel disease How to tailor treatment for patients and ensure optimum management of Crohn’s disease and ulcerative colitis.…
Forces driving the evolution of biologics into biosimilars and biobetters As demand for biologics increases, manufacturers are devising strategies to maximise their returns on investment and benefit patients.…
